Tenaya Therapeutics, Inc. (TNYA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TNYA Stock Price Chart Interactive Chart >
TNYA Price/Volume Stats
Current price | $3.12 | 52-week high | $16.17 |
Prev. close | $3.24 | 52-week low | $1.64 |
Day low | $3.03 | Volume | 225,800 |
Day high | $3.33 | Avg. volume | 278,229 |
50-day MA | $2.36 | Dividend yield | N/A |
200-day MA | $4.57 | Market Cap | 129.09M |
Tenaya Therapeutics, Inc. (TNYA) Company Bio
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Latest TNYA News From Around the Web
Below are the latest news stories about TENAYA THERAPEUTICS INC that investors may wish to consider to help them evaluate TNYA as an investment opportunity.
Tenaya Therapeutics up 6% following director stock purchase
|
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 MilestonesPhase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301 Anticipated in Second Half 2023 TN-401 IND Submission Planned in Second Half 2023 Cash Runway Extended into First Half 2025 SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and |
Insiders who placed huge bets on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) earlier this year would be disappointed with the 23% dropThe recent price decline of 23% in Tenaya Therapeutics, Inc.'s ( NASDAQ:TNYA ) stock may have disappointed insiders who... |
Tenaya Therapeutics Inc. (NASDAQ:TNYA) Adds 8.49% In A Week: What’s Lifting The Stock?In last trading session, Tenaya Therapeutics Inc. (NASDAQ:TNYA) saw 0.49 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.30 trading at -$0.07 or -2.95% at ring of the bell on the day assigns it a market valuation of $158.93M. That closing price of TNYA’s stock is … Tenaya Therapeutics Inc. (NASDAQ:TNYA) Adds 8.49% In A Week: What’s Lifting The Stock? Read More » |
Tenaya Therapeutics Appoints Amy Burroughs to Board of DirectorsSOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. |
TNYA Price Returns
1-mo | 85.71% |
3-mo | 9.09% |
6-mo | -34.59% |
1-year | -69.68% |
3-year | N/A |
5-year | N/A |
YTD | 55.22% |
2022 | -89.39% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
2018 | N/A |
Loading social stream, please wait...